China-based, global contract research, development and manufacturing Company (CRDMO) WuXi Biologics (2269.HK) announced on Thursday that it has been honoured by the environmental non-profit CDP for leadership in corporate transparency and performance on water security.
WuXi Biologics has been granted a place on the organisation's annual 'A List' for the second year.
According to CDP's scoring methodology, companies are evaluated on their awareness of environmental issues, management methods and advancements in environmental stewardship. Assessments are conducted across four levels that represent the steps a company moves through on its action journey: Disclosure (D-/D score), Awareness (C-/C score), Management (B-/B score), Leadership (A/A- score).
Based on data reported through the CDP 2024 Assessment Questionnaire, WuXi Biologics achieved a score of 'A' for Water Security, standing out among over 25,000 companies evaluated.
Dr Chris Chen, WuXi Biologics CEO and chairman of its ESG Committee, said, 'We are very pleased to be named once again on the CDP Water Security 'A' list, an acknowledgement that further inspires our steadfast dedication to enhancing our sustainability performance. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide to fulfill ESG commitments, and jointly work with all stakeholders to promote responsible practices throughout the entire value chain.'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business
Insmed receives highest ranking in Science's 2024 Top Employers Survey
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions